Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis
- 16 January 2007
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 104 (3) , 967-972
- https://doi.org/10.1073/pnas.0607542104
Abstract
Angiostatic therapies designed to inhibit neovascularization associated with multiple pathological conditions have only been partially successful; complete inhibition has not been achieved. We demonstrate synergistic effects of combining angiostatic molecules that target distinct aspects of the angiogenic process, resulting in the complete inhibition of neovascular growth associated with development, ischemic retinopathy, and tumor growth, with little or no effect on normal, mature tissue vasculature. Tumor vascular obliteration using combination angiostatic therapy was associated with reduced tumor mass and increased survival in a rat 9L gliosarcoma model, whereas individual monotherapies were ineffective. Significant compensatory up-regulation of several proangiogenic factors was observed after treatment with a single angiostatic agent. In contrast, treatment with combination angiostatic therapy significantly reduced compensatory up-regulation. Therapies that combine angiostatic molecules targeting multiple, distinct aspects of the angiogenic process may represent a previously uncharacterized paradigm for the treatment of many devastating diseases with associated pathological neovascularization.Keywords
This publication has 36 references indexed in Scilit:
- T2-TrpRS Inhibits Preretinal Neovascularization and Enhances Physiological Vascular Regrowth in OIR as Assessed by a New Method of QuantificationInvestigative Opthalmology & Visual Science, 2006
- Angiogenesis in life, disease and medicineNature, 2005
- Bevacizumab in the treatment of colorectal cancerExpert Opinion on Biological Therapy, 2005
- Inhibitors of Ocular NeovascularizationJAMA, 2005
- Antineovascular therapy, a novel antiangiogenic approachEmerging Therapeutic Targets, 2005
- Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic TherapyScience, 2005
- Convection-Enhanced Delivery of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand with Systemic Administration of Temozolomide Prolongs Survival in an Intracranial Glioblastoma Xenograft ModelCancer Research, 2004
- Intra-arterial delivery of endostatin gene to brain tumors prolongs survival and alters tumor vessel ultrastructureGene Therapy, 2004
- Loss of p53 Compensates for αv-Integrin Function in Retinal NeovascularizationJournal of Biological Chemistry, 2002
- PRECLINICAL AND PHASE 1A CLINICAL EVALUATION OF AN ANTI-VEGF PEGYLATED APTAMER (EYE001) FOR THE TREATMENT OF EXUDATIVE AGE-RELATED MACULAR DEGENERATIONRetina, 2002